EOLS

AI Memo

Evolus

As of 2026-09-11/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Evolysse adoption and portfolio cross-selling • 2027-03-31

Base target: $11 / p=50% prob

Biggest risk

The company remains small and execution-sensitive, operating expenses increased sequentially, cash declined during Q2, and part of reported gross margin benefited from a tariff refund. Long-dated portfolio programs require regulatory investment, while the September open-market sale by CEO David Moatazedi adds a modest sentiment overhang [#SEC-FORM4-2026-09-04].

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Q2 revenue grew 21%, adjusted EBITDA was positive for a third consecutive quarter, and management raised revenue and gross-margin guidance. Sustained Jeuveau growth, Evolysse adoption and portfolio cross-selling could validate a scalable multi-product aesthetics platform.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-11

Base target

$11

p=50%

Bull target

$15

p=30%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Delivery against raised 2026 outlook
International expansion and Profhilo development
Q2 revenue grew 21%, adjusted EBITDA was positive for a third consecutive quarter, and management raised revenue and gross-margin guidance.

BearKey bullets

CEO David Moatazedi sold 105,108 shares at $9.0385 on September 2, 2026; the Form 4 does not establish motive, but the transaction may weigh on sentiment [#SEC-FORM4-2026-09-04].
Cash decreased to $45.2 million from $49.8 million sequentially in stored earnings coverage, while continued commercial, international and development investment may constrain financial flexibility.
Failure to achieve the raised $330 million-$337 million 2026 revenue outlook or the 67.0%-67.5% adjusted gross-margin range could reverse the post-Q2 operating thesis.

WatchKey bullets

Evolysse adoption and portfolio cross-selling

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $11 (p=50%)

Target spread vs base: +43% / -48%

Scenario probabilities

Bull Target: $15 (p=30%)Base Target: $11 (p=50%)Bear Target: $6 (p=20%)

Commentary

Primary-source operating tone remains constructive after the August Q2 release, but subsequent evidence is thin. The $7.91 September 10 anchor is below the CEO's September 2 sale price and well below the unverified-count $15 analyst median. Reliable social coverage, options skew, short interest, employee sentiment and post-print analyst revisions are unavailable; unavailable numeric sentiment fields are represented as zero rather than measured neutral readings. This remains a cautious monitoring thesis, not a high-conviction rerating call.

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Delivery against raised 2026 outlook
International expansion and Profhilo development

Scenarios

Bull Target (Scenario probability)

$15 / p=30% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$6 / p=20% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
Evolysse adoption and portfolio cross-selling
Q2 injectable-gel revenue reached $8.9 million, with stored earnings coverage attributing sequential growth to greater penetration, reorders and utilization. Continued adoption alongside Jeuveau would support the diversified commercial-platform thesis [#PR-EARNINGS-2026-08-06].
Prob 62.00% • Move 16.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Delivery against raised 2026 outlook
2026-12-31
Evolus reported Q2 global net revenue of $84.1 million, up 21%, and a third consecutive quarter of positive adjusted EBITDA. Management raised 2026 revenue guidance to $330 million-$337 million and adjusted gross-margin guidance to 67.0%-67.5%; execution against these targets is the principal near-term rerating test [#SEC-8K-2026-08-05].
Prob 68% • Move 14% • Priced-in 55%

Long-term Catalysts

Months to a year

International expansion and Profhilo development
2030-12-31
Evolus expanded its injectable portfolio through Profhilo, with anticipated U.S. commercialization in 2030, and broadened Estyme rights into Canada, Australia and New Zealand with expected commercialization in 2028. These initiatives expand the addressable portfolio but carry long-duration regulatory and execution risk [#SEC-8K-2026-08-05].
Prob 42% • Move 35% • Priced-in 15%

Risks

CEO David Moatazedi sold 105,108 shares at $9.0385 on September 2, 2026; the Form 4 does not establish motive, but the transaction may weigh on sentiment [#SEC-FORM4-2026-09-04].
Cash decreased to $45.2 million from $49.8 million sequentially in stored earnings coverage, while continued commercial, international and development investment may constrain financial flexibility.
Failure to achieve the raised $330 million-$337 million 2026 revenue outlook or the 67.0%-67.5% adjusted gross-margin range could reverse the post-Q2 operating thesis.
Profhilo requires a full U.S. premarket-approval process and is not expected to commercialize until around 2030, leaving substantial regulatory, timing and execution risk.
Q2 gross margin benefited from an approximately 120-basis-point tariff refund, creating risk that reported profitability overstates the underlying run rate.
Tariff uncertainty and the decision to bring roughly one year of Jeuveau inventory into the United States may increase inventory, payables and working-capital volatility.

Peers

Symbol	Summary
AMGN	Large diversified biopharma benchmark useful for broad healthcare risk appetite, but its scale and product mix make it a weak operating comparable for Evolus.
GILD	Large commercial biopharma benchmark with limited comparability to Evolus's cash-pay injectable-aesthetics portfolio.
CCCC	Similar-market-cap biotechnology reference, but a clinical-stage business rather than a direct commercial-aesthetics peer; valuation comparison should carry little weight.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

AMGN

Large diversified biopharma benchmark useful for broad healthcare risk appetite, but its scale and product mix make it a weak operating comparable for Evolus.

GILD

Large commercial biopharma benchmark with limited comparability to Evolus's cash-pay injectable-aesthetics portfolio.

CCCC

Similar-market-cap biotechnology reference, but a clinical-stage business rather than a direct commercial-aesthetics peer; valuation comparison should carry little weight.